RPA-601 by Rocket Pharmaceuticals for Cardiomyopathy: Likelihood of Approval
RPA-601 is under clinical development by Rocket Pharmaceuticals and currently in Phase I for Cardiomyopathy. According to GlobalData, Phase I drugs for Cardiomyopathy have an 86% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData's report assesses how RPA-601's drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.RPA-601 overviewRPA-601 is under development for the treatment of PKP2-associated arrhythmogenic cardiomyopathy. It comprises adeno associated virus (AAV.rh74) delivering the gene encoding plakophilin 2 pathogenic variants (PKP2-ACM). It is administered through intravenous route.Rocket Pharmaceuticals overviewRocket Pharmaceuticals (Rocket Pharma), formerly Inotek Pharmaceuticals Corp is a clinical-stage biopharmaceutical company. It focuses on gene therapies for rare and devastating diseases. The company has three clinical-stage ex vivo lentiviral vector (“LVV”) programs which include programs for Fanconi Anemia (“FA”), a genetic defect in the bone marrow that reduces the production of blood cells or promotes the production of faulty blood cells, Leukocyte Adhesion Deficiency-I (“LAD-I”), a genetic disorder that causes the immune system to malfunction, and Pyruvate Kinase Deficiency (“PKD”), a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. It also has a clinical-stage in vivo adeno-associated virus (“AAV”) program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. Rocket Pharma is headquartered in Cranbury, New Jersy, the US. For a complete picture of RPA-601's drug-specific PTSR and LoA scores, buy the report here.
RPA-601 is under clinical development by Rocket Pharmaceuticals and currently in Phase I for Cardiomyopathy.
What's Your Reaction?
